방사선유전체학 시장 : 전략적 인사이트 및 예측(2026-2035년)

The Radiogenomics Market is forecast to grow at a CAGR of 14.8%, reaching USD 8.87 billion in 2035 from USD 2.56 billion in 2026.

The global radiogenomics market is experiencing rapid growth, driven by the convergence of advanced medical imaging, genomic sequencing, and artificial intelligence. Radiogenomics represents an emerging multidisciplinary field that combines radiology, genomics, bioinformatics, and artificial intelligence to improve disease characterization across multiple therapeutic areas. The market primarily focuses on oncology, where imaging-derived biomarkers increasingly complement genomic profiling to support diagnosis, prognosis, treatment selection, and longitudinal disease monitoring. Demand is expanding because healthcare systems are adopting precision medicine models that require integrated interpretation of imaging and molecular information rather than isolated diagnostic assessments. Conventional diagnostic pathways limit clinical insight because tissue biopsies provide localized molecular information while imaging captures whole-tumor heterogeneity without revealing genomic alterations. Healthcare organizations are investing in radiomics software, cloud-based analytics, machine learning, and next-generation sequencing platforms that strengthen integration between imaging and genomic datasets. Regulatory agencies are strengthening oversight for artificial intelligence-enabled diagnostic software, patient data governance, and clinical validation because radiogenomics increasingly influences personalized treatment decisions and biomarker-driven healthcare.

Market Drivers

Growing Adoption of Precision Oncology

• Precision oncology requires comprehensive tumor characterization because treatment selection increasingly depends on understanding both molecular alterations and imaging phenotypes. Demand is increasing as clinicians integrate radiogenomic analysis into oncology workflows to identify imaging biomarkers associated with genomic mutations and therapeutic response. Conventional biopsy-based diagnostics limit longitudinal disease assessment because repeated tissue sampling is invasive and may not fully represent tumor heterogeneity. Healthcare institutions are expanding artificial intelligence platforms, radiomics software, and genomic sequencing capabilities that improve multidisciplinary clinical decision-making while supporting personalized treatment strategies. Radiogenomics strengthens precision oncology by enabling comprehensive, non-invasive evaluation throughout the patient care pathway.

Increasing Integration of Artificial Intelligence in Medical Imaging

• Artificial intelligence enhances radiogenomics because machine learning algorithms identify imaging features that correlate with complex genomic signatures beyond human interpretation. Demand is increasing as healthcare providers adopt AI-enabled radiomics platforms to improve diagnostic accuracy and predictive analytics across oncology and neurological disorders. Manual image interpretation creates analytical limitations because subtle imaging biomarkers frequently remain undetected within conventional radiological assessment. Technology companies are developing deep learning models, automated feature extraction platforms, and cloud-based image analytics that improve reproducibility while supporting genomic prediction. Artificial intelligence strengthens radiogenomics by enabling scalable analysis of multidimensional clinical datasets.

Rising Investments in Genomic Medicine

• Genomic medicine provides the molecular foundation for radiogenomics because imaging biomarkers require validated genomic correlations to generate clinically meaningful insights. Demand is increasing as governments, research organizations, and healthcare providers expand genomic sequencing programs supporting precision healthcare initiatives. Independent genomic analysis reduces clinical efficiency because molecular findings require complementary phenotypic information to improve therapeutic decision-making. Healthcare organizations are integrating sequencing technologies, bioinformatics, and radiological analytics that improve interpretation while supporting personalized medicine. Radiogenomics expands clinical value by combining structural imaging with genomic intelligence to improve disease characterization.

Expansion of Quantitative Imaging Biomarkers

• Quantitative imaging biomarkers improve objective disease assessment because standardized imaging metrics support reproducible clinical evaluation across healthcare systems. Demand is increasing as pharmaceutical companies and academic institutions incorporate radiomics into biomarker discovery and clinical research programs. Conventional qualitative imaging interpretation introduces variability because subjective assessment reduces consistency across observers and institutions. Imaging software developers are expanding automated feature extraction, image standardization, and advanced computational analytics that improve biomarker validation while strengthening clinical confidence. Quantitative imaging strengthens radiogenomics by providing measurable phenotypic indicators that complement molecular diagnostics.

Market Restraints

• Limited availability of standardized imaging acquisition protocols and radiomics validation frameworks reduces reproducibility across healthcare institutions. Integration challenges between imaging archives, genomic databases, and clinical information systems increase implementation complexity and operational costs. Regulatory uncertainty surrounding artificial intelligence-based clinical decision support and imaging biomarker validation extends commercialization timelines.

Technology and Segment Insights

By Imaging Modality

• Magnetic Resonance Imaging (MRI) represents the leading imaging modality because it provides superior soft tissue contrast and multiparametric imaging that enables detailed characterization of tumor biology. Demand is increasing as oncology centers utilize MRI-derived radiomic features to predict molecular subtypes, therapeutic response, and disease progression. Healthcare providers are integrating advanced MRI techniques, artificial intelligence, and radiomics analytics with genomic sequencing platforms that improve prediction of molecular biomarkers. Computed Tomography (CT), Positron Emission Tomography (PET), and PET/CT are also significant modalities, each offering unique quantitative biomarkers.

By Genomic Technology

• Next-Generation Sequencing (NGS) represents the largest genomic technology segment because comprehensive genomic profiling forms the molecular foundation of radiogenomic analysis. Demand is increasing as healthcare providers utilize NGS to identify genomic alterations that correlate with imaging biomarkers and therapeutic response. Whole genome sequencing, whole exome sequencing, transcriptomics, and multi-omics platforms represent additional critical technologies.

By Application

• Oncology dominates the radiogenomics market because cancer management increasingly depends on combining imaging biomarkers with genomic profiling to personalize diagnosis, treatment selection, and disease monitoring. Demand is increasing as clinicians integrate radiomics, AI, and molecular diagnostics to predict tumor aggressiveness and therapeutic response. Neurology, cardiovascular diseases, and rare and genetic disorders represent growing application areas.

Competitive and Strategic Outlook

• The competitive landscape features major medical imaging and genomic technology companies. GE HealthCare Technologies Inc. differentiates itself through its broad portfolio of diagnostic imaging systems and AI-enabled software. Koninklijke Philips N.V. maintains a strong position through integrated imaging, digital pathology, and healthcare informatics. Canon Medical Systems Corporation focuses on high-performance imaging technologies. Fujifilm Holdings Corporation combines medical imaging, digital pathology, and AI. Illumina, Inc. provides the genomic foundation through its next-generation sequencing technologies. F. Hoffmann-La Roche Ltd. integrates molecular diagnostics and pharmaceutical expertise. Thermo Fisher Scientific Inc. offers a broad portfolio of genomic technologies and bioinformatics.
• Strategic developments include increasing integration of AI and cloud-based analytics, expansion of multi-omics platforms, and growth of liquid biopsy integration. Companies are forming partnerships to enhance interoperability, clinical validation, and healthcare data integration. Product launches focus on AI-enabled radiomics platforms, integrated diagnostic solutions, and precision medicine applications. Companies that successfully combine imaging excellence, genomic expertise, and scalable digital infrastructure are expected to lead the market.

Conclusion

• The radiogenomics market is poised for substantial growth, driven by the adoption of precision oncology, AI integration, and genomic medicine expansion. The evolution from isolated imaging and genomic analysis toward integrated, AI-powered diagnostic platforms is reshaping precision healthcare. Companies that successfully deliver validated, interoperable, and clinically actionable radiogenomic solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding digital health infrastructure will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Radiogenomics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Precision Medicine Landscape
• 3.8 Oncology Biomarker Landscape
• 3.9 Imaging Biomarkers and Genomic Correlation
• 3.10 Clinical Adoption Landscape
• 3.11 Patient Journey Analysis in Precision Oncology

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Artificial Intelligence in Radiogenomics
• 6.2 Radiomics and Quantitative Imaging Advances
• 6.3 Multi-Omics Integration
• 6.4 Digital Pathology Integration
• 6.5 Cloud-Based Image Analytics
• 6.6 Machine Learning & Deep Learning Applications
• 6.7 Emerging Imaging Biomarkers
• 6.8 Product Innovation
• 6.9 Clinical Trial Analysis
• 6.10 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Radiogenomics Market Landscape Analysis

• 8.1 Analysis by Imaging Modality
• 8.2 Analysis by Genomic Technology
• 8.3 Analysis by Biomarker Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Artificial Intelligence Integration

9. Radiogenomics Market Segment Analysis (2021-2035)

• 9.1 By Imaging Modality
  • 9.1.1 Magnetic Resonance Imaging (MRI)
  • 9.1.2 Computed Tomography (CT)
  • 9.1.3 Positron Emission Tomography (PET)
  • 9.1.4 Positron Emission Tomography-Computed Tomography (PET/CT)
  • 9.1.5 Other Imaging Modalities
• 9.2 By Genomic Technology
  • 9.2.1 Next-Generation Sequencing (NGS)
  • 9.2.2 Whole Genome Sequencing
  • 9.2.3 Whole Exome Sequencing
  • 9.2.4 Transcriptomics
  • 9.2.5 Multi-Omics Platforms
• 9.3 By Application
  • 9.3.1 Oncology
  • 9.3.2 Neurology
  • 9.3.3 Cardiovascular Diseases
  • 9.3.4 Rare & Genetic Disorders
  • 9.3.5 Other Applications
• 9.4 By End User
  • 9.4.1 Hospitals
  • 9.4.2 Academic & Research Institutes
  • 9.4.3 Diagnostic Imaging Centers
  • 9.4.4 Pharmaceutical & Biotechnology Companies
  • 9.4.5 Contract Research Organizations (CROs)

10. Radiogenomics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Radiogenomics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 China
• 11.10 Japan
• 11.11 South Korea
• 11.12 India
• 11.13 Australia
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Siemens Healthineers AG
• 13.2 GE HealthCare Technologies Inc.
• 13.3 Koninklijke Philips N.V.
• 13.4 Canon Medical Systems Corporation
• 13.5 Fujifilm Holdings Corporation
• 13.6 Illumina, Inc.
• 13.7 F. Hoffmann-La Roche Ltd.
• 13.8 Thermo Fisher Scientific Inc.
• 13.9 QIAGEN N.V.
• 13.10 SOPHiA GENETICS SA
• 13.11 Tempus AI, Inc.
• 13.12 Agilent Technologies, Inc.
• 13.13 ConcertAI
• 13.14 Ibex Medical Analytics Ltd.
• 13.15 Paige AI, Inc.

14. Radiogenomics Market Commercial Forecast Analysis

• 14.1 MRI-Based Radiogenomics
• 14.2 CT-Based Radiogenomics
• 14.3 PET/PET-CT-Based Radiogenomics
• 14.4 AI-Enabled Radiogenomics Platforms
• 14.5 Multi-Omics Integrated Radiogenomics Solutions

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends